CPT code 17261 covers the destruction of a malignant cutaneous lesion on the trunk, arms, or legs measuring 0.6–1.0 cm in diameter using methods such as chemosurgery, cryosurgery, electrosurgery, or other destructive techniques. This code is used broadly across outpatient dermatology and ambulatory care settings to bill for targeted lesion destruction and is relevant for national claims, coverage policy, and clinical documentation because accurate coding affects clinical reporting, reimbursement, and quality measurement for skin cancer management.

Key payers in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of standard clinical context for lesion destruction, common site-of-service considerations, and payer coverage touchpoints. The publication also summarizes benchmark rate ranges, policy and coverage updates that affect use of the code, and documentation elements needed to support medical necessity. Practical insights include comparisons to adjacent codes for different lesion sizes or anatomical locations and notes on billing nuances relevant to outpatient dermatologic practice.

Data not available in the input for associated taxonomies, ICD-10 diagnoses, or detailed payer-specific payment rates is noted where applicable.